Ganglioside GM2

Ganglioside GM2 is a lipid of Sphingolipids (SP) class. Ganglioside gm2 is associated with abnormalities such as Sensory neuropathy, Neuropathy, Autoimmune Diseases, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating and Neuromuscular Diseases. The involved functions are known as Pressure- physical agent, Cytolysis, Inflammation, Complement-Dependent Cytotoxicity and conjugation. Ganglioside gm2 often locates in Membrane, Entire nervous system, Cell surface, Biopsy sample and Lipid Bilayers. The associated genes with Ganglioside GM2 are anti-IgM, Polypeptides, Transgenes, Alleles and Homologous Gene. The related lipids are Ganglioside GA2, QS 21, sulfate-3-glucuronyl paragloboside, Lipopolysaccharides and IV(4)-galactosyl-N-acetylganglioside GD1a. The related experimental models are Disease model.

References related to abnormalities published in Others

PMID	Journal	Published Date	Author	Title
25425650	J. Biol. Chem.	2015	Grey M et al.	Acceleration of α-synuclein aggregation by exosomes.
16614007	J. Neurol. Neurosurg. Psychiatry	2006	Kaida K et al.	Anti-ganglioside complex antibodies in Miller Fisher syndrome.
11711493	Hypertension	2001	Gouni-Berthold I et al.	Gangliosides GM1 and GM2 induce vascular smooth muscle cell proliferation via extracellular signal-regulated kinase 1/2 pathway.
11696012	Biochem. J.	2001	Li SC et al.	Degradation of G(M1) and G(M2) by mammalian sialidases.
11254608	Infect. Immun.	2001	Ang CW et al.	Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
9673245	Infect. Immun.	1998	Prendergast MM et al.	Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.
10751257	Neurology	2000	Ang CW et al.	Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome.
27923633	Brain Res.	2017	Trilck M et al.	Diversity of glycosphingolipid GM2 and cholesterol accumulation in NPC1 patient-specific iPSC-derived neurons.
27491075	Dis Model Mech	2016	Wolf H et al.	A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
26175473	J. Lipid Res.	2015	Anheuser S et al.	Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity.
25873306	ASN Neuro		Rockwell HE et al.	AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.
25717099	Sci Transl Med	2015	Vite CH et al.	Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease.
25418946	J Gene Med		McIntyre C et al.	Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.
24813327	Clin Neurol Neurosurg	2014	Vachalová I et al.	Anti-GM2, -GD1a and -GD1b positive purely isolated facial diplegia.
24769373	Anal. Biochem.	2014	Fuller M et al.	Liquid chromatography/electrospray ionisation-tandem mass spectrometry quantification of GM2 gangliosides in human peripheral cells and plasma.
23401234	Synapse	2013	Rupp A et al.	The effects of age and ganglioside composition on the rate of motor nerve terminal regeneration following antibody-mediated injury in mice.
22372857	J. Neurochem.	2012	Saito M et al.	Elevation of GM2 ganglioside during ethanol-induced apoptotic neurodegeneration in the developing mouse brain.
21487393	Mol. Ther.	2011	Matsuoka K et al.	Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis.
20430897	J. Biol. Chem.	2010	Vitner EB et al.	Common and uncommon pathogenic cascades in lysosomal storage diseases.
20187655	ACS Chem. Biol.	2010	Ho CW et al.	Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors.
19706290	Biochem. Biophys. Res. Commun.	2009	Tomioka R et al.	Neuroblastoma GOTO cells are hypersensitive to disruption of lipid rafts.
18368480	Glycoconj. J.	2008	Komori T et al.	Design and efficient synthesis of novel GM2 analogues with respect to the elucidation of the function of GM2 activator.
18241673	Clin. Biochem.	2008	Gu J et al.	Simultaneous quantification of GM1 and GM2 gangliosides by isotope dilution tandem mass spectrometry.
17253773	Biochemistry	2007	Martinez Z et al.	GM1 specifically interacts with alpha-synuclein and inhibits fibrillation.
17196574	Clin. Chim. Acta	2007	Tsuji D et al.	Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
16620986	Mol. Immunol.	2007	López-Requena A et al.	Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study.
14722612	J. Clin. Invest.	2004	Yamaguchi A et al.	Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses.
14552811	J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.	2003	Mauri L et al.	Procedure for separation of GM2 ganglioside species with different ceramide structures by a flash reversed-phase silica gel liquid chromatography.
12740812	Chembiochem	2003	Antoine T et al.	Large-scale in vivo synthesis of the carbohydrate moieties of gangliosides GM1 and GM2 by metabolically engineered Escherichia coli.
12705795	Intern. Med.	2003	Mizutani K et al.	Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2.
12455030	Int. J. Cancer	2003	Chen HH et al.	Suppression of lung metastasis of mouse Lewis lung cancer P29 with transfection of the ganglioside GM2/GD2 synthase gene.
11828255	Melanoma Res.	2002	Mehta RR et al.	In vitro transformation of human congenital naevus to malignant melanoma.
11578853	Brain Dev.	2001	Taniguchi M et al.	Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain.
11560770	Hum. Gene Ther.	2001	Teixeira CA et al.	Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant.
11425192	Glycoconj. J.	2000	Hedberg KM et al.	Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro.
11230488	J. Clin. Oncol.	2001	Kirkwood JM et al.	High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
10073593	J. Am. Soc. Nephrol.	1999	Mundel TM et al.	Ganglioside GM2-activator protein and vesicular transport in collecting duct intercalated cells.
9989797	J. Invest. Dermatol.	1999	Takahashi T et al.	IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.
9972876	Neurochem. Res.	1999	Usuki S et al.	GM2 promotes ciliary neurotrophic factor-dependent rescue of immortalized motor neuron-like cell (NSC-34).
9797137	Int. J. Cancer	1998	Hanibuchi M et al.	Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice.
9728970	J. Neurol. Neurosurg. Psychiatry	1998	Tsukaguchi M et al.	IgM anti-GM2 antibody in a patient with Guillain-Barré syndrome subsequent to cytomegalovirus hepatitis cross reacts with N-acetylgalactosaminyl GD1a.
9668352	Ann. N. Y. Acad. Sci.	1998	Walkley SU et al.	GM2 ganglioside as a regulator of pyramidal neuron dendritogenesis.
9572057	Mol Med Today	1998	Chavany C and Jendoubi M	Biology and potential strategies for the treatment of GM2 gangliosidoses.
9435988	Clin. Chim. Acta	1997	Sandhoff K and Kolter T	Biochemistry of glycosphingolipid degradation.
8971173	Cancer Res.	1996	Nishinaka Y et al.	Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment.
8757036	Neurology	1996	De Gasperi R et al.	Late-onset GM2 gangliosidosis: Ashkenazi Jewish family with an exon 5 mutation (Tyr180-->His) in the Hex A alpha-chain gene.
8620627	Clin. Immunol. Immunopathol.	1996	Kimata H and Yoshida A	Inhibition of spontaneous immunoglobulin production by ganglioside GM2 in human B cells.
7492324	Biochem. J.	1995	Haraguchi M et al.	The effects of the site-directed removal of N-glycosylation sites from beta-1,4-N-acetylgalactosaminyltransferase on its function.
8544979	Neuroscience	1995	Walkley SU	Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivity.
7590782	Hybridoma	1995	Alfonso M et al.	T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies.
1291049	Carbohydr. Res.	1992	Schaeper RJ et al.	In vitro biosynthesis of GbOse4Cer (globoside) and GM2 ganglioside by the (1-->3) and (1-->4)-N-acetyl beta-D-galactosaminyltransferases from embryonic chicken brain. Solubilization, purification, and characterization of the transferases.